Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis
- PMID: 21814496
- PMCID: PMC3144197
- DOI: 10.1371/journal.pmed.1001063
Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis
Abstract
David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.
Conflict of interest statement
MP is co-chair of the Stop TB Partnership's New Diagnostics Working Group and a consultant for the Bill & Melinda Gates Foundation, which had no involvement in this manuscript. MP also serves as an editorial board member on
Figures


References
-
- Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med. 2010;16:271–284. - PubMed
-
- World Health Organization. Framework for implementing new tuberculosis diagnostics. Geneva: WHO; 2010. Available: http://www.who.int/tb/laboratory/whopolicyframework_july10_revnov10.pdf. Accessed 24 June 2011.
-
- World Health Organization. WHO endorses new rapid tuberculosis test. 2010. Available: http://www.who.int/tb/features_archive/new_rapid_test/en/. Accessed 13 March 2011.